XCath Secures $30 Million Series C to Improve Global Outcomes in Neurovascular Care
Latest funding will support additional development and future commercialization of XCath’s endovascular surgical robot HOUSTON–(BUSINESS WIRE)–XCath, a medical device company pioneering neuro-endovascular surgical robotics, announced today that it has secured $30 million in Series C…